Table 1.

Baseline clinical characteristics of the study population.

	Placebo (N=29)	Vitamin E (N=30)	p-value#
Age, years	46±11	47±10	0.60
Gender, female %	58.6%	60.0%	0.91
Race, White %	82.8%	80.0%	0.79
Ethnicity, Hispanic %	6.9%	20.0%	0.13
BMI, kg/m2	35.5±7.1	35.0±7.5	0.80
HTN, %	58.6%	66.7%	0.52
IGT, %	48.3%	56.7%	0.52
Serum ALT, IU/L	74.9±37.0	87.6±47.3	0.26
Serum AST, IU/L	49.4±25.4	57.0±29.5	0.30
HOMA-IR	4.9±3.9	5.7±4.5	0.46*
Histological scores
Hepatocyte ballooning, grade 0, 1, 2 %	17.2%; 34.5%; 48.3%	16.7%; 36.7%; 46.7%	0.98
Fibrosis, stage 0, 1, 2, 3 %	13.8%; 31.0%; 34.5%; 20.7%	6.7%; 40.0%; 30.0%; 23.3%	0.75

#: p-values were from t-test or Chi-square test, except for

^*(Wilcoxon Rank-sum test). BMI: body mass index, IGT: impaired glucose tolerance, HTN: systemic hypertension, HOMA- IR: Homeostasis Model of Assessment - Insulin Resistance